STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

FILE PHOTO: Dr. Ben Carson sits in as Republican presidential candidate and former U.S. President Donald Trump calls in to a ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

One of the most remarkable aspects of the populist alliance between Robert F. Kennedy Jr. and Donald Trump is that it puts ...

WASHINGTON — Newly empowered Republican leadership in the White House and in Congress will likely bring some good news and ...

Robert F. Kennedy Jr. has vowed to combat "the chronic disease epidemic in this country" in the Trump administration, with ...

The rapid progress in AI has also facilitated real-life applications within the pharmaceutical industry that may lead to ...

Yuhan Corp. posted record-breaking third-quarter results, with revenue reaching 598.8 billion won and operating profit ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN).

Drug shortages in the U.S. are increasing in number and duration, primarily affecting generic and multi-sourced drugs that ...

BEIJING -- China has highlighted its commitment to encouraging the long-term operation and development of foreign-funded ...